Business
Devonian Health Group Reports its Fourth Quarter and Annual 2025 Financial Results and Appointment of a New Board Member
Devonian Health Group Reports its Fourth Quarter and Annual 2025 Financial Results and Appointmen...
About this update from Devonian Health Group, Inc.
[{"type":"text","content":"\n\n\nDevonian Health Group Reports its Fourth Quarter and Annual 2025 Financial Results and Appointment of a New Board Member\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\nCanada NewsWire\n\n\nFourth quarter distribution revenues of $1.3 millionFourth quarter net loss of $0.4 million, $0.003 per shareAnnual distribution revenues of $23.6 millionAnnual net loss of $6 million, $0.041 per shareDevonian is debt free with $7 million in cash as of July 31, 2025Pierre Labbé appointed as a new board memberQUÉBEC, Nov. 26, 2025 /CNW/ - Devonian Health Group Inc. (\"Devonian\" or the \"Corporation\") (TSXV: GSD) (OTCQB: DVHGF), a biopharmaceutical corporation specializing in the development of prescription drugs targeting inflammatory diseases today announced financial results for its fourth quarter and fiscal year ended July 31, 2025.\n\n\n\n\n\n\n\nManagement Comments\n\"Our year-end results reflect a company that is financially disciplined, debt-free, and strategically positioned for the next phase of value creation. With this strong foundation, we are intensifying our efforts to advance Thykamine™'s added-value programs in the fibro-inflammatory space—an area where unmet medical needs remain significant. Our team is committed to executing with excellence as we continue building momentum and delivering on our long-term vision for Devonian.\" said Dr. Andre Boulet, Chairman and Chief Executive Officer of Devonian.\nBusiness Highlights \nCompleted preclinical studies aimed at demonstrating new potential applications of Thykamine™ across additional inflammatory diseases, including MASH and fibrosis.Focusing on the Thykamine™ phase 2/3 study in pediatric mild-to-moderate atopic dermatitis (eczema)Securing additional patent protection related to mechanisms of action and other therapeutic applicationsAppointment of Mr. Pierre Labbé, CPA as member of the Board of Directors. Mr. Jean Forcione has resigned. We thank him for his collaborationContinuing the distribution of two (2) products through Altius, namely the Pantoprazole Magnes...